Lupin Recalls Quinapril Tablets Due to Unknown Impurity Exceeding Limits
Lupin Pharmaceuticals is recalling Quinapril 10 mg tablets because stability testing revealed an unknown impurity above specification limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls without specific reports of hospitalization or serious injury fall into the High severity category, representing a risk of temporary or medically reversible adverse health consequences.
Plain-English summary
Lupin Pharmaceuticals, Inc. is recalling Quinapril Tablets USP, 10 mg, 90 count bottles (NDC 68180-557-09). The recall involves 22,896 bottles distributed nationwide and in Puerto Rico. The specific lot affected is 3110358 with an expiration date of 12/13.
The recall was initiated because stability testing identified an unknown impurity that exceeded the specification limit at the 36-month test interval. This is classified as an FDA Class II recall, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Consumers who have this specific lot of Quinapril should stop using it and contact their healthcare provider or pharmacist for guidance. The product is a prescription medication, so patients should not discontinue treatment without consulting a medical professional.
The recalled product
- Product
- QUINAPRIL (QUINAPRIL)
- Brand
- QUINAPRIL
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot 3110358 Exp. 12/13
UPCs (2)
- 0368180559092
- 0368180556091
Distribution
Part of a larger recall action
This product is one of 2 recalled by Lupin Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · QUINAPRIL
- HighQuinapril Tablets Recalled Due to Excess Impurity Above Limits
FDA (Drugs) · 2022-12-28
- HighPrescription Drug Quinapril Recalled for Chemical Impurity Exceeding Safety Limits
FDA (Drugs) · 2022-12-28
- ModerateLupin Recalls Quinapril Tablets Due to Impurity A Specification Failure
FDA (Drugs) · 2017-04-12
- HighLupin Recalls Quinapril Tablets Due to Unknown Impurity
FDA (Drugs) · 2014-01-22
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateSertraline tablets recalled because bottle seals are not adhering
FDA (Drugs) · 2025-12-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17